Abstract:
Community-acquired pneumonia is an urgent problem that requires effective
treatment. For effective treatment of pneumonia, it is necessary to choose the right
fluoroquinolone, taking into account the sensitivity of the pathogen and the
pharmacokinetic characteristics of the drug. In this case, it is necessary to take into
account the pronounced side effects and limitations of the use of these drugs. An
important step is to determine the dosage and duration of treatment. The
effectiveness and safety of treatment of pneumonia with fluoroquinolones is
manifested in clinical and laboratory parameters. This article reviews a
comparative study of moxifloxacin with levofloxacin in the treatment of
community-acquired pneumonia, and compares the effectiveness and safety of
these drugs.
